Joana Vindeirinho, PhD,  —

The global prevalence of Rett syndrome is estimated to be 7.1 cases per 100,000 female individuals, according to the first known meta-analysis ever done to estimate the number of girls and women worldwide with the rare neurodevelopmental disorder. This finding “may facilitate planning of therapeutic trials in this disease,…

The Rett Syndrome Research Trust (RSRT) was granted $500,000 to help test the Emerald biosensor’s ability to accurately measure symptoms of Rett syndrome. The donation was provided by Alba Tull, chair of the Tull Family Foundation and founder of First Light Capital Group. It will fund a…

The U.S. Food and Drug Administration (FDA) has cleared Neurogene’s investigational new drug application for NGN-401, an experimental gene therapy for Rett syndrome. This paves the way for the therapy to be tested in a planned Phase 1/2 clinical trial in girls with Rett syndrome, to begin later…